Atossa Genetics Inc. (ATOS): Price and Financial Metrics


Atossa Genetics Inc. (ATOS): $0.77

0.00 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATOS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATOS Stock Price Chart Interactive Chart >

Price chart for ATOS

ATOS Price/Volume Stats

Current price $0.77 52-week high $2.31
Prev. close $0.77 52-week low $0.75
Day low $0.75 Volume 242,700
Day high $0.77 Avg. volume 1,325,921
50-day MA $0.83 Dividend yield N/A
200-day MA $1.02 Market Cap 96.91M

Atossa Genetics Inc. (ATOS) Company Bio


Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.


ATOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ATOS Latest Social Stream


Loading social stream, please wait...

View Full ATOS Social Stream

Latest ATOS News From Around the Web

Below are the latest news stories about ATOSSA THERAPEUTICS INC that investors may wish to consider to help them evaluate ATOS as an investment opportunity.

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date incl

Yahoo | November 7, 2022

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. “This investment in DCT is an important step in pursuing our st

Yahoo | November 1, 2022

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseasesSEATTLE, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and adjunctive treatments for cancer radiotherapy, announces today that it has retained Richard Graydon, M.D.,

Yahoo | October 25, 2022

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th QuarterSEATTLE, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of its Phase 2 neoadjuvant clinical study of (Z)-endoxife

Yahoo | October 24, 2022

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | October 21, 2022

Read More 'ATOS' Stories Here

ATOS Price Returns

1-mo -11.27%
3-mo -15.64%
6-mo -23.00%
1-year -60.10%
3-year -46.53%
5-year -80.56%
YTD -51.88%
2021 68.42%
2020 -39.49%
2019 53.92%
2018 -67.68%
2017 -81.35%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9104 seconds.